Blueprint Medicines (BPMC) IPO Opens Up 30%

Blueprint Medicines' (Nasdaq: BPMC) IPO opened for trading at $23.40 after pricing 8,145,834 shares of its common stock at $18.

Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers for the offering. JMP Securities is acting as a co-manager for the offering. Wedbush PacGrow is also acting as a co-manager for the offering.

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

You May Also Be Interested In

• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO
• TD Cowen: '2Q26 Digital Ad Expert Call: Resilient Consumer Continues to Drive Ad Spend'
• Medtronic, Inc. (MDT) PT Lowered to $100 at TD Cowen